Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Phase of Trial: Phase IV
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Susoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Baxalta
- 12 Dec 2017 Results (n=19) of second preliminary data assessing safety, safety related factors, utilisation and effectiveness of rpFVIII, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 03 Nov 2017 Planned End Date changed from 1 Nov 2019 to 1 Aug 2019.
- 03 Nov 2017 Planned primary completion date changed from 1 Nov 2019 to 1 Aug 2019.